Last reviewed · How we verify
NCT05176704
Development and Validation of a Novel Functional Eye-Tracking Software Application for Alzheimer's Disease
trial testing Eye-Tracking in Alzheimer's Disease in 250 participants. Status unknown.
3 March 2024
Quick facts
| Lead sponsor | Innodem Neurosciences |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 250 |
| Start date | 15 April 2022 |
| Primary completion | 3 March 2024 |
| Estimated completion | 3 March 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Eye-Tracking
Conditions studied
- Alzheimer's Disease — all drugs for Alzheimer's Disease →
Sponsor
Innodem Neurosciences
Who can join
18 and older, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by Alzheimer's Disease and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of Alzheimer's Disease and associated cognitive changes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05176704
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Eye-Tracking
Trials testing the same drug.
- NCT07110493 — Study of Visual Perception Phenomena: Phosphene Mapping Induced by TMS and Its Relationship With Eye Movements · NA · recruiting
- NCT06283524 — Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis · completed
- NCT06256731 — ETNA-MS Device Validation Study · completed
- NCT05661266 — Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis · completed
- NCT05186948 — Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairme · terminated
Other recruiting trials for Alzheimer's Disease
Currently open trials in the same condition.
- NCT07457138 — Lombard Cohort of Brain Health Services · recruiting
- NCT07234942 — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants Wit · Phase 1 · recruiting
- NCT07479914 — Art of Memory for Cognitive Enhancement in the Monza Brain Health Service · NA · active not recruiting
- NCT07214727 — A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease · Phase 1 · recruiting
- NCT07105709 — Open-label Extension Study in Participants With Early Alzheimer's Disease · Phase 2 · recruiting
Other Innodem Neurosciences trials
Trials by the same sponsor.
- NCT06283524 — Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis · completed
- NCT06256731 — ETNA-MS Device Validation Study · completed
- NCT05661266 — Investigating Eye-Movement Biomarkers of Disease Severity and Cognition in Multiple Sclerosis · completed
- NCT05212727 — Development and Validation of a Novel Functional Eye-Tracking Software Application for Neurological Disorders · terminated
- NCT05186948 — Development and Validation of a Novel Functional Eye-Tracking Software Application for Cancer-related Cognitive Impairme · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05176704 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Innodem Neurosciences
- Last refreshed: 13 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05176704.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing